Original Development Brief – Amends the Public Health Service Act to authorize sickle cell surveillance, prevention, and treatment initiatives and to establish conditions for collaboration with community-based organizations on such initiatives.
Original Development Brief – Examines and provides recommendations on the scientific, ethical, and social issues raised by human genome editing and assesses the capacity of governance systems to ensure the responsible development and use of this technology.
Original Development Brief – Grants FDA approval to the 23andMe Personal Genome Service (PGS) test as a Class II medical device for ten diseases and conditions and outlines special controls to mitigate risks involved.
Original Development Brief – Promotes and facilitates stem cell research showing evidence of substantial clinical benefit to patients, while placing restrictions on the creation, injury, and destruction of embryos for such research.
Updated lastJune 25, 2018
for the 06/15/2017 version of HR 2918 and the 05/24/2018 version of S 2956.
Original Development Brief – Requires additional labeling of genetically engineered salmon in the marketplace and calls for independent review of FDA environmental assessments leading to the approval of fish genetically engineered for human consumption.